|
Drug Platform for L-Asparaginases for the Treatment of Leukemias
Application
A novel humanized therapeutic L-asparaginase compound to treat acute lymphoblastic leukemia (ALL) and other cancers.
Key Benefits
A novel drug discovery platform for developing asparaginase-based compounds to treat leukemias and other cancers.
The derivatives could exhibit less immunogenicity and systemic toxicity than FDA-approved...
Published: 3/1/2024
Contributor(s): Sunil Raikar, Christopher Doering, H. (Harold) Trent Spencer, Kristopher Knight, Harrison Brown
|
|
Combination of Tetrahydrobiopterin and Arginine/ ± Arginase Inhibitors for the Treatment of COVID-19
Application
A novel drug combination to address acute arginine/BH4 dysregulation that develops with COVID-19 and MIS-C infection.
Key Benefits
Potential to improve outcomes of those infected with COVID-19 with few side effects.
Repurposing opportunity with the combination of two approved drugs (tetrahydrobiopterin and arginine).
Addresses...
Published: 4/8/2024
Contributor(s): Claudia Morris, Lou Ann Brown
|
|
Small Molecule Inhibitors of NADPH Oxidase 4 (NOX4) Signaling
Application
Small molecule inhibitors of NOX4 signaling with a wide array of therapeutic potential.
Key Benefits
Small molecule inhibitors of NOX4 signaling.
Low cytotoxicity.
Market Summary
The NADPH oxidase 4 (NOX4) has gained considerable and growing attention during the past years because of its potential key involvement in a variety of...
Published: 12/1/2023
Contributor(s): Bernard Lassegue, Kathy Griendling, David Brown, Qian Xu, Osman Guner, J. Phillip Bowen, Amol Kulkarni, E. Blake Watkins
|